LONDON (Alliance News) - AstraZeneca PLC on Tuesday said the European Commission has granted marketing authorisation for its Zavicefta antibiotic for patients with serious Gram-negative bacterial infections.
The approval covers the treatment of adult patients suffering complicated intra-abdominal infections, complicated urinary tract infections and aerobic Gram-negative infections in adults with limited treatment options.
"Zavicefta is an important addition to the arsenal of antibiotics in the global fight against antimicrobial resistance. Effective treatment options are rapidly running out for serious Gram-negative infections. Zavicefta helps bridge that gap and allows a broad population of patients across Europe to benefit from this new medicine," said Hans Sijbesma, managing director of the antibiotics business unit at AstraZeneca.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)